Clinical Trials

630 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05139017 2026-05-22

waveLINE-003

Phase 2/3 Recruiting

290 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06717347 2026-05-22

MK-2140-010

1,046 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06890884 2026-05-22

MK-2140-011

594 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06911502 2026-05-20

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

400 enrolled

Lymphoma, Follicular

NCT06091254 2026-05-19

OLYMPIA-1

822 enrolled

Lymphoma, Follicular

NCT07226843 2026-05-19

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

Phase 1 Recruiting

460 enrolled

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT04002297 2026-05-18

MANGROVE

510 enrolled

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT05947851 2026-05-18

BELLWAVE-010

735 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06651970 2026-05-18

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

Phase 4 Recruiting

60 enrolled

Heart Failure, Lymphatic Diseases, Leukemia, B-Cell

NCT06091865 2026-05-15

OLYMPIA-3

904 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06790420 2026-05-15

RITUXIMAB BS Intravenous Infusion 100mg・500mg [Pfizer] Post-marketing Database Study

Completed

2,703 enrolled 13 charts

Infections, Lymphoma

NCT06564038 2026-05-14

Soundtrack-E

Phase 1/2 Recruiting

408 enrolled

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT02970318 2026-05-11

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

310 enrolled 18 charts 1 FDA

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06230224 2026-05-11

OLYMPIA-4

216 enrolled

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT06846671 2026-05-11

CaDAnCe-302

250 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06970743 2026-05-11

CaDAnCe-303

150 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03274492 2026-05-08

POLARIX

Phase 3 Completed

1,000 enrolled 1 FDA

Lymphoma, Large B-Cell, Diffuse

NCT05171647 2026-05-07

SUNMO

208 enrolled 12 charts

Lymphoma, Non-Hodgkin

NCT07029737 2026-05-07

SOUND-MCL

55 enrolled

Phase 2/3 Active not recruiting

Lymphoma, Mantle-Cell

NCT04442022 2026-05-06

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

501 enrolled

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05283720 2026-05-06

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

496 enrolled

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06149286 2026-05-06

OLYMPIA-5

470 enrolled

Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Marginal Zone

NCT06191744 2026-05-06

EPCORE™FL-2

1,095 enrolled

Phase 1/2 Active not recruiting

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

NCT04542824 2026-05-05

EPCORE™ NHL-3

78 enrolled

Phase 1/2 Active not recruiting

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04623541 2026-05-05

EPCORE™ CLL-1

195 enrolled

Phase 1/2 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04663347 2026-05-05

EPCORE™ NHL-2

543 enrolled

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT04712097 2026-05-05

Celestimo

478 enrolled

Lymphoma, Follicular, Recurrence

NCT05952024 2026-05-05

ACRUE

80 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05533775 2026-05-04

iMATRIX GLO

Phase 1/2 Recruiting

65 enrolled

Recurrence

NCT06084936 2026-05-04

GLOBRYTE

182 enrolled